2021
DOI: 10.1097/cmr.0000000000000759
|View full text |Cite
|
Sign up to set email alerts
|

Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis

Abstract: Pembrolizumab is a monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression. Common side effects include headache, insomnia, dizziness, fatigue, cough, dyspnea, inappetence, nausea, vomiting, constipation, diarrhea, abdominal pain, itching, rash, chills. arthralgia, myalgia, fever, infections, sepsis, vitiligo, anemia, hyperglycemia, hyponatremia, hypoalbuminemia, hypertriglyceridemia and elevated transaminases. Hypothyroidism as a side effect of the immune-ch… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 11 publications
0
0
0
Order By: Relevance